Filing Flows › Coherus Oncology (CHRS) › Q2 2025
Coherus Oncology (CHRS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Coherus Oncology (CHRS) reported revenue of $10.3M for the second quarter 2025 (Q2 2025), -0.4% from a year earlier and +35% from the quarter before. Operating margin was -443.6%.
Coherus Oncology, Q2 2025: revenue $10.3M (-0.4% year over year), operating margin -443.6%, net earnings $298M, operating cash flow −$46.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.3M | +35% | -0.4% |
| Operating profit | −$45.5M | — | — |
| Net earnings | $298M | — | — |
| Operating cash flow | −$46.6M | — | — |
What changed
Revenue was $10.3M in Q2 2025, roughly flat year over year and up 35% from the previous quarter. Toripalimab was the largest line at 97% of revenue. Other revenue lost $6.2M year over year (down 95%), 14790% of the total change.
Operating costs exceeded revenue by $45.5M, an operating margin of -443.6%. Total costs grew 12% against flat revenue. The fastest-growing cost line was Cost of revenue (+88%). Net earnings were $297.8M.
Operating cash flow was −$46.6M. Non-cash charges added back $300K of depreciation and amortization and $5.4M of share-based compensation. Working capital and other items used $350.1M.
Questions
What was Coherus Oncology's revenue in the second quarter 2025?
Coherus Oncology (CHRS) reported revenue of $10.3M for the second quarter 2025 (Q2 2025), -0.4% from a year earlier and +35% from the quarter before.
Was Coherus Oncology profitable in the second quarter 2025?
Operating loss was $45.5M (-443.6% of revenue) and net earnings $298M.
Source: Coherus Oncology 10-Q on SEC EDGAR.